NEUROMUSCULAR BLOCKADE AND INTUBATION CONDITIONS OF THE SINGLE BOLUS DOSE (2xED90) OF ROCURONIUM BROMIDE.

Rocuronium bromide (2xED90), a new non depolarising neuromuscular blocking drug with rapid onset, intermediate duration of action and cardiostability was studied in open randomised trial in 30 patients. Neuromuscular block was monitored using a Train of Four stimulus by stimulator electrodes placed on the ulnar never close to the wrist. Intubation conditions were assessed subjectively by scoring the jaw relaxation, vocal cord and the response to intubation with same technique of anaesthesia. Clinical recovery (Dur25) of neuromuscular blockade was monitored. Haemodynamic changes were recorded. Intubation conditions were clinically acceptable in 99.6% of patients, (excellent 73%; good 26.6%) at 90s. Time to onset (Lag time) of neuromuscular block was 22.5 ± 12.6 sec and average time for the onset of block (maximum effect) was 90.9 ±10.6 sec. The duration of clinical muscular relaxation (25% recovery of twitch height) was 22.4 ± 8.30 min. Stability of cardiocirculatory system was seen.

RCT Entities:   Population Interventions Outcomes